Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Morgan Stanley Initiates Coverage On Trevi Therapeutics with Overweight Rating, Announces Price Target of $18

Author: Benzinga Newsdesk | August 21, 2025 07:16am
Morgan Stanley analyst Judah Frommer initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Overweight rating and announces Price Target of $18.

Posted In: TRVI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist